Central Nervous System Lymphoma Pipeline Landscape: Advancing Therapeutics for an Aggressive and Rare Brain Malignancy | DelveInsight

Central Nervous System Lymphoma (CNSL), particularly Primary CNS Lymphoma (PCNSL), is a rare and aggressive form of extranodal non-Hodgkin lymphoma that originates within the brain, spinal cord, leptomeninges, or eyes. Most commonly manifesting as diffuse large B-cell lymphoma (DLBCL), CNSL is characterized by rapid progression, poor prognosis in relapsed/refractory cases, and challenges associated with drug delivery across the blood-brain barrier.

Current management is centered around high-dose methotrexate-based chemotherapy, often in combination with rituximab and/or cytarabine. While initial responses can be promising, relapse is common, and long-term survival remains limited in refractory settings, underscoring the urgent need for novel therapies with better CNS penetration and durable efficacy.

Encouragingly, the drug development landscape for CNSL is evolving, driven by a deeper understanding of disease biology and CNS-specific treatment barriers. Targeted therapies such as ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, are demonstrating clinical activity in relapsed/refractory settings. Immunomodulatory agents like pomalidomide, checkpoint inhibitors including nivolumab, and experimental CD19-directed CAR-T cell therapies are emerging as promising options in clinical trials. These agents aim to improve both systemic control and intracranial tumor responses while reducing long-term neurotoxicity.

DelveInsight's "Central Nervous System Lymphoma - Pipeline Insight, 2025" provides an in-depth analysis of the evolving R&D landscape. The report highlights the most advanced pipeline therapies in development, ranging from targeted small molecules and biologics to adoptive cell therapies. It also explores innovations in CNS drug delivery, biomarker-driven trial designs, regulatory incentives, and the role of academic-industry collaborations shaping the future of CNSL treatment.

As the therapeutic pipeline matures, the shift from conventional cytotoxic regimens toward more personalized and targeted strategies is poised to transform the management of CNS lymphoma, offering renewed hope for improved survival and quality of life in a historically underserved patient population.

Interested in learning more about the current treatment landscape and the key drivers shaping the central nervous system lymphoma pipeline? Click here: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Central Nervous System Lymphoma Pipeline Report
• DelveInsight's Central Nervous System Lymphoma pipeline analysis depicts a strong space with 13+ active players working to develop 13+ pipeline drugs for Central Nervous System Lymphoma treatment.
• The leading Central Nervous System Lymphoma companies include Shandong New Time Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Janssen, Celgene, and others are evaluating their lead assets to improve the Central Nervous System Lymphoma treatment landscape.
• Key Central Nervous System Lymphoma pipeline therapies in various stages of development include ACP-01, Stem cell therapies, BLNP-016, ATI-1013, CLBS12, tirabrutinib, and others.
• In March 2025, Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.
• In March 2023, ONO PHARMA USA announced that its BTK inhibitor, tirabrutinib (ONO-4059), received Orphan Drug Designation from the FDA for treating primary central nervous system lymphoma (PCNSL).

Request a sample and discover the recent breakthroughs happening in the central nervous system lymphoma pipeline landscape at https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Central Nervous System Lymphoma Overview
Central Nervous System Lymphoma (CNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma that originates in or spreads to the brain, spinal cord, leptomeninges, or eyes without systemic involvement at diagnosis. Most cases are classified as primary CNS lymphoma (PCNSL) and are predominantly of the diffuse large B-cell lymphoma (DLBCL) subtype. The disease typically presents with neurological deficits, cognitive changes, or visual symptoms, depending on the lesion's location.

Diagnosis involves brain imaging, cerebrospinal fluid analysis, and biopsy, while treatment primarily includes high-dose methotrexate-based chemotherapy with or without whole-brain radiotherapy. Despite initial responsiveness, CNSL is often associated with high relapse rates and limited long-term survival, particularly in older adults. Emerging therapies aim to improve outcomes through targeted agents, immunotherapies, and blood-brain barrier-penetrant regimens, reflecting a growing need for more effective and durable treatment strategies in this high-risk population.

Find out more about central nervous system lymphoma medication at https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Central Nervous System Lymphoma Treatment Analysis: Drug Profile
F520: Shandong New Time Pharmaceutical
F520 is a humanized monoclonal antibody that targets the PD-1 receptor, developed by Shandong New Time Pharmaceutical. It is currently in Phase II clinical trials for the treatment of primary and secondary central nervous system lymphoma.

Tirabrutinib (Velexbru): Ono Pharmaceuticals
Tirabrutinib, marketed as Velexbru, is an oral, highly selective BTK inhibitor developed by Ono Pharmaceuticals. It targets B-cell receptor (BCR) signaling, which is critical for B-cell survival and function. Approved in Japan in 2020 for relapsed or refractory primary central nervous system lymphoma (PCNSL), tirabrutinib is also being evaluated in a Phase II clinical trial in the U.S. for PCNSL.

Learn more about the novel and emerging central nervous system lymphoma pipeline therapies at https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Central Nervous System Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Central Nervous System Lymphoma Pipeline Report
• Coverage: Global
• Key Central Nervous System Lymphoma Companies: Shandong New Time Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Janssen, Celgene, and others.
• Key Central Nervous System Lymphoma Pipeline Therapies: ACP-01, Stem cell therapies, BLNP-016, ATI-1013, CLBS12, and others.

Dive deep into rich insights for drugs used for central nervous system lymphoma treatment, visit: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Central Nervous System Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Central Nervous System Lymphoma Pipeline Therapeutics
6. Central Nervous System Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Central Nervous System Lymphoma Pipeline: Mid-Stage Products (Phase II)
8. Central Nervous System Lymphoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.